{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:41Z","timestamp":1786119161760,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/wnf.0b013e3180616570","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:16:26Z","timestamp":1236190586000},"page":"295-300","source":"Crossref","is-referenced-by-count":38,"title":["Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and \"Wearing Off\" Symptoms"],"prefix":"10.1097","volume":"30","author":[{"given":"William G.","family":"Ondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil D.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Kricorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease.","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/mds.20383","article-title":"Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.","volume":"20","author":"Stacy","year":"2005","journal-title":"Mov Disord"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/1531-8257(199907)14:4<605::AID-MDS1009>3.0.CO;2-H","article-title":"Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years.","volume":"14","author":"Reardon","year":"1999","journal-title":"Mov Disord"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.","volume":"20","author":"Moller","year":"2005","journal-title":"Mov Disord"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00002826-199106000-00005","article-title":"L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.","volume":"14","author":"Cedarbaum","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s007020170018","article-title":"Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.","volume":"108","author":"Kupsch","year":"2001","journal-title":"J Neural Transm"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0006-8993(98)01089-0","article-title":"Effect of selegiline on dopamine concentration in the striatum of a primate.","volume":"815","author":"Kaseda","year":"1999","journal-title":"Brain Res"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/0929867023371481","article-title":"The influence of metabolism on the MAO-B inhibitory potency of selegiline.","volume":"9","author":"Haberle","year":"2002","journal-title":"Curr Med Chem"},{"key":"R10-7-20210203","first-page":"657","article-title":"Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites.","volume":"25","author":"Shin","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"suppl 2","key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1007\/s100720200099","article-title":"Clinical assessment of dysphagia in early phases of Parkinson's disease.","volume":"23","author":"Volonte","year":"2002","journal-title":"Neurol Sci"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0303-8467(97)80006-6","article-title":"Swallowing difficulty in Parkinson's disease.","volume":"99","author":"Fuh","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1212\/WNL.39.8.1109","article-title":"Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.","volume":"39","author":"Golbe","year":"1989","journal-title":"Neurology"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease.","volume":"66","author":"Paalhagen","year":"2006","journal-title":"Neurology"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00702-003-0042-6","article-title":"A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00702-003-0036-4","article-title":"A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.20036","article-title":"Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.","volume":"19","author":"Waters","year":"2004","journal-title":"Mov Disord"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-198810000-00001","article-title":"Deprenyl as symptomatic therapy in Parkinson's disease.","volume":"11","author":"Golbe","year":"1988","journal-title":"Clin Neuropharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200709000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:41:51Z","timestamp":1786038111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200709000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3180616570","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}